2023-07-03

Interview and presentation with questions and answers in collaboration with Uddaaktier

CEO Anna Eriksrud makes a short presentation of NeoDynamics and answers questions regarding the rights issue in an interview in collaboration with Uddaaktier on Monday, July 3rd, at 7 p.m.

The interview will be streamed live via: live.uddaaktier.com

Uddaaktier will ask questions to Anna Eriksrud, but viewers will also have the chance to ask questions. The interview will be conducted in Swedish.

It is also possible to watch the interview afterwards via Uddaaktier's YouTube channel: https://www.youtube.com/channel/UCgprMaNfKDJmG0Tp5pzB-Dg

About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.